Equities research analysts at Barclays Capital (NYSE: BCS) lifted their price target on shares of Vertex Pharmaceuticals (NASDAQ: VRTX) from $44.00 to $77.00 in a research note issued to investors on Tuesday. The firm currently has an “overweight” rating on the stock.
A number of other firms have also recently commented on VRTX. Analysts at Wells Fargo & Co. (NYSE: WFC) upgraded shares of Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note to investors on Tuesday. Separately, analysts at Morgan Stanley (NYSE: MS) upgraded shares of Vertex Pharmaceuticals from an “underweight” rating to an “equal weight” rating in a research note to investors on Tuesday. They now have a $51.00 price target on the stock. Finally, analysts at Needham & Company upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note to investors on Tuesday. They now have a $65.00 price target on the stock.
Shares of Vertex Pharmaceuticals opened at 64.16 on Tuesday. Vertex Pharmaceuticals has a one year low of $26.50 and a one year high of $64.50. The company has a market cap of $13.529 billion and a P/E ratio of 45.63.
Vertex Pharmaceuticals last issued its quarterly earnings data on Thursday, April 26th. The company reported $0.43 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.57 by $0.14. The company’s quarterly revenue was up 496.5% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals will post $0.72 earnings per share next quarter.
Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.